Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory disease, which is characterized by not fully reversible airflow limitation, inflammatory cells infiltration, mucus overproduction and airway remodeling[@b1]. As a complex disease, the precise molecular mechanism of COPD is still unknown. However, it was widely accepted that the occurrence of COPD relied on the interaction of gene and environment.

Protease and anti-protease imbalance was considered as an important mechanism involved in the pathogenesis of COPD. Since the discovery of relationship between a α 1-antitrypsin and COPD, no other proteases or anti-proteases have been confirmed to be associated with this disease[@b2]. Matrix metalloproteinase (MMP) is a group of protease, which mediate various physiological and pathological processes. So far, at least 24 kinds of MMPs have been identified in human[@b3]. Increasing evidence from animal experiments suggested that MMPs played a pivotal role in COPD[@b4][@b5][@b6][@b7][@b8][@b9][@b10][@b11].

The activity of MMPs is dependent on the gene encoding them. The existence of gene polymorphism determines the different expression level of these genes among individuals, which ultimately result in different phenotype of disease in a population. In the past decade, considerable efforts have been made to find out the relationship between MMP single nucleotide polymorphism (SNP) and COPD risk in several populations[@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32]. However, the results of different researches were not consistent. Some reports showed that specific MMP genotype was related to occurrence of COPD[@b13][@b14][@b19][@b23][@b27][@b31][@b32], while other reports did not support the association between MMP polymorphism and COPD susceptibility[@b12][@b15][@b16][@b17][@b18][@b20][@b21][@b22][@b24][@b25][@b26][@b28][@b29][@b30]. These contradictory findings may be partly due to limited sample size, false-positive results and publication bias. In order to identify which MMP polymorphism play the key role in COPD occurrence, we conducted a comprehensive meta-analysis to quantify the overall risk of MMP polymorphisms on COPD.

Results
=======

Characteristics of included studies
-----------------------------------

We identified 123 related articles, of which 30 studies were potentially appropriate. 7 studies did not examine any MMP single nucleotide polymorphism (SNP) mentioned above. 3 studies were excluded because of lack of proper control. Further more, 2 repeated studies were also ruled out. Finally, 3 additional studies by manual search were added to analysis. Thus, 21 studies including 4184 cases and 5716 controls met the including criteria ([Figure 1](#f1){ref-type="fig"}). MMP1 SNP and MMP9 SNP were both mentioned in 12 studies, while 5 and 6 studies provided the association of MMP3 and MMP12 SNPs with COPD, respectively. The study characteristics were listed in [Table 1](#t1){ref-type="table"}. COPD patients were diagnosed through lung function index in all studies expect two by Enewold *et al.*[@b15] and Minematsu *et al*.[@b24], respectively. Population and hospital based controls were involved in different studies. In addition, frequency-matched controls to the cases by ethnicity, sex, age and smoking status were applied in some studies. A classical polymerase chain reaction -- restriction fragment length polymorphism (PCR-RFLP) assay was performed in 15 of the 21studies.

Overall effects for alleles and genotypes
-----------------------------------------

The distribution of alleles and genotypes of each study was listed in [Table 2](#t2){ref-type="table"}. Due to existence of moderate to high heterogeneity among studies, the random effect model was used to evaluate the odds ratio. For all the four MMP polymorphisms, we did not find the distribution of alleles was related to COPD risk (i.e. MMP1 1G versus 2G: OR 0.99, 95% CI 0.89--1.10, p = 0.81) ([Table 3](#t3){ref-type="table"}). On the other hand, we did not observe a significant association between genotypes and COPD risk through a series of comparisons, including dominant model (i.e. MMP9 CC versus CT + TT: OR 0.80, 95% CI 0.57--1.14, p = 0.22), recessive model (i.e. MMP9 CC + CT versus TT: OR 0.75, 95% CI 0.45--1,24, p = 0.26), and homozygote model (i.e. MMP9 CC versus TT: OR 0.71, 95% CI 0.40--1.24, p = 0.23) ([Table 3](#t3){ref-type="table"}).

Subgroup analysis
-----------------

To exclude the effect of confound factors, such as genetic background, smoking index, lung function, detection methods etc., subgroup analysis was introduced to further elucidate the relationship between MMP SNPs and the risk of COPD. We divided included studies into 2 to 3 subgroups according to ethnicity (Asian or Caucasian), smoking index (matched or not), age (matched or not), lung function (FEV~1~/prediction%) and genotype detection method (RFLP or not).

For the MMP9 -1562C/T polymorphism, ethnicity and smoking index did not affect the distribution of alleles and genotypes between COPD patients and controls. Although age did not affect the distribution of alleles in these two subpopulations, it did affect genotypes distribution, especially for TT genotype. In age matched subgroup, carriers of C allele had much lower susceptibility of COPD, compared with TT homozygotes (CC + CT vs. TT: OR 0.56, 95% CI 0.33--0.96, p = 0.03; CC vs. TT: OR 0.44, 95% CI 0.25--0.77, p = 0.004) ([Figure 2a--b](#f2){ref-type="fig"}). Just like age, lung function also affected TT genotype distribution in two subpopulations. In one subgroup where COPD patients with relatively worse lung function (FEV1 \< 50% prediction), carriers of C allele were at much lower risk of COPD, compared with TT homozygotes (CC + CT vs. TT: OR 0.60, 95% CI 0.37--0.99, p = 0.05; CC vs. TT: OR 0.53, 95% CI 0.31--0.88, p = 0.01) ([Figure 2 c--d](#f2){ref-type="fig"}). The method of genotype identification seemed to be another factor that related to the genotype distribution in the two subpopulations. The risk of COPD was lower among carriers of C allele than that among TT homozygotes in the subgroup where RFLP was used to detect genotype (CC + CT vs. TT: OR, 0.61, 95% CI 0.41--0.92, p = 0.02; CC vs. TT: OR0.54, 95% CI 0.35--0.82, p = 0.004) ([Figure 2 e--f](#f2){ref-type="fig"}).

For the MMP1 -1607 1G/2G polymorphism, all the factors mentioned above seemed not to be associated with the distribution of both alleles and genotypes between COPD patients and controls ([Supplementary Table S1](#s1){ref-type="supplementary-material"}).

For the MMP3 and MMP12 polymorphisms, we did not carry out subgroup analysis because of limited number of studies.

Heterogeneity analysis
----------------------

For MMP9 -1562C/T polymorphism, I^2^ showed a moderate variation under most comparisons when we performed overall and subgroup analysis. However, in the subgroup of Caucasian, there was almost no variation. Moreover, in the age matched, worse lung function and RFLP subgroup, no heterogeneity was detected except for the comparison between CC and CT + TT (I^2^ \> 80% in these subgroups) ([Table 3](#t3){ref-type="table"}, [Supplementary Table S2](#s1){ref-type="supplementary-material"}).

For the overall and subgroup analysis of MMP1 -1607 1G/2G polymorphism, I^2^ showed a moderate variation under most comparisons. In the subgroup of Caucasian and non-RFLP, no variation was found except for the comparison between 1G1G and 1G2G + 2G2G (I^2^ = 29% in Caucasian subgroup and I^2^ = 31% in non-RFLP subgroup, respectively). For the subgroup analysis of age and lung function, I^2^ showed low or no heterogeneity under different comparisons in different subgroups ([Table 3](#t3){ref-type="table"}, [Supplementary Table S1](#s1){ref-type="supplementary-material"}).

For overall analysis of MMP3 -1171 5A/6A and MMP12 -82A/G polymorphism, I^2^ showed a low or moderate variation under all comparisons ([Table 3](#t3){ref-type="table"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed to test the effect of a specific study on the overall results. There were six studies not exhibiting Hardy--Weinberg equilibrium (HWE) (5 for MMP1 -1607 1G/2G and 1 for MMP9 -1562 C/T). However, omitting these studies did not significantly alter the pooled OR value in both polymorphisms. Although the genotypes distribution of MMP9 -1562 C/T in the study reported by Lee *et al.* was not deviate from HWE, we found this study affected the general results obviously. If this study was excluded, the pooled OR decreased from 0.75 to 0.61 under the comparison of CC + CT vs. TT (95% CI: 0.41--0.92, p = 0.02) and from 0.71 to 0.54 under the comparison of CC vs. TT (95% CI: 0.35--0.82, p = 0.004). ([Supplementary Figure S1](#s1){ref-type="supplementary-material"})

Publication bias
----------------

Publication bias was detected by Begg\'s and Egger\'s test. These tests did not show significant results in almost all comparisons ([Table 3](#t3){ref-type="table"}). The shape of funnel plots did not reveal evidence of obvious asymmetry ([Figure 3](#f3){ref-type="fig"}). These results indicated little publication bias.

Discussion
==========

In order to seek out the genetic variants related to COPD, much effort has been made to explore the association between gene polymorphism via case-control study or cohort study. Recently, several genome-wide association studies (GWAS) have identified novel SNPs located in chromosomal loci 15q25 with genome-wide significance for association with COPD[@b33][@b34][@b35]. However, we have not found any data about the association between MMP and COPD based on GWAS.

Matrix metalloproteinase is a family of zinc-dependent endopeptidases degrading all the main protein components of the extracellular matrix and playing an essential role in tissue remodeling and repair associated with development and inflammation[@b36]. MMP-1, MMP3 and MMP-12 are located in close proximity on chromosome 11 while MMP-9 is located on chromosome 20 ^3^. Many clinical studies suggested that MMPs were involved in COPD as concentration of MMPs in serum or induced sputum in patients was higher than that in non-COPD patients or healthy volunteers[@b37][@b38][@b39][@b40]. The degree of COPD severity is dependent on lung function. Joos *et al*. reported that MMP1 -1607 1G/2G polymorphism was associated with the rate of decline in lung function, and the haplotypes consisting of MMP1 -1607 1G/2G and MMP12 + 357Asn/Ser polymorphism were also related to lung function decline rate[@b41]. On the other hand, Hunninghake *et al*. found that the minor allele (G) of a functional variant in the promoter region of MMP12 was associated with a reduced risk of COPD in the NAS cohort consisting of initially healthy adult men and a cohort of smokers[@b42]. Variation in gene promoter region might cause the change of protein activity, which was considered to be associated with COPD susceptibility.

However, from the results of present analysis, we failed to find correlation between genotypes of various MMP family members and the risk of COPD. It was a negative result, but was in accordance with the results of majority studies included in this analysis. Although the remaining studies showed significant association between certain genotype and COPD susceptibility, it could not be ruled out the existence of false positive results due to the reasons as follows. First, some studies contained a small sample size, so the results might not stable enough. Second, different detection methods in different studies were the source of deviation, which affected overall results. Third, the positive results reported by some authors were contradictory. For example, Minematsu[@b24] and Cheng[@b13] reported that CC was a protective genotype, while Lee[@b23] and Zhou[@b32] suggested that CC was a susceptible genotype. Due to these paradoxical results, no significant overall effect could be obtained.

The great discrepancy among different studies indicated the existence of heterogeneity. In fact, moderate to high heterogeneity was detected in almost all comparisons. Subgroup analysis was introduced to further seek out the source of heterogeneity. For the analysis of MMP9 and MMP1 polymorphism, all the studies were divided into subgroups according to ethnicity, age, smoking index, lung function and methods for genotype identification. After stratification, the heterogeneity of at least one subgroup reduced or disappeared. It demonstrated that these factors were at least part source of heterogeneity. In addition, we also found in some subgroups, including age matched subgroup, worse lung function subgroup and RFLP subgroup, the carriers of allele C had much less risk of COPD. It was worth to note that the distribution of MMP9 genotypes in COPD patients with worse lung function is different from that in normal people and patients with better lung function. In fact, one report by Korytina (2008) *et al.*[@b21] showed that in very sever COPD patients (FEV~1~ \< 30% prediction) the allele T was more frequency. So it may provide us the direction to selecting proper subpopulation of COPD.

Hardy--Weinberg equilibrium (HWE) results showed the p values of several studies were less than 0.05, which suggested the potential to influence the overall effect. Sensitivity analysis showed that these studies had minor effect on OR values, which indicated the stability of present work. Unexpectedly, another report greatly affected the main results. For MMP9 polymorphism, removing Lee\'s report would contribute to evident change of results. Apart from the inconsistency of some demography indexes between COPD cases and control subjects, this study used a unique method for genotype identification. It was the only study that did not use PCR-RFLP to analyze MMP9 genotype. This deficiency might partly explain the results mentioned above, but further research was needed to elucidate the discrepancy among these studies.

There were some limitations in the present analysis. First, the sample size was too small. The quantity of patients in these studies was just more than 4000. However, it was estimated that there were about 200 million COPD patients in the world. In other words, only a small part of patients were recruited to study. Second, the existence of confound factors severely affected the ultimate results. As discussed above, age, lung function, and even detection method were demonstrated to be confounders in present analysis. These confounders were present in almost every study we selected. Third, the data we obtained now were not comprehensive. Almost all the studies were either on Asian or Caucasian. African was one of the three largest ethnics on the earth, but so far we have found only one article on African. Moreover, the occurrence of COPD is not depend on one gene but a cluster of genes, so the gene linkage is important for exploring disease pathogenesis. However, we are lack of related data, which may prevent us from further research.

In conclusion, our present analyses did not show significant association between MMP SNPs and COPD risk in the whole population. However, we found TT genotype of MMP9 was a risk factor in the subpopulation with relatively worse lung function. So, it may be helpful to screen out potential severe COPD patients by detecting MMP9 genotype. In light of various deficiencies in present studies, there is a great need of further studies including large population, selecting appropriate control subjects, unifying detection method and paying much attention to gene linkage in order to confirm the role of MMP SNPs in the COPD susceptibility.

Methods
=======

Search strategy
---------------

We carried out a comprehensive search strategy in various databases including Pubmed, Embase, Cochrane Library and China National Knowledge Infrastructure (CNKI) to seek out the articles which were about the association between MMP polymorphisms and the risk of COPD. The terms we used as follows: "chronic obstructive pulmonary disease", "COPD", "emphysema", "chronic bronchitis"; "matrix metalloproteinase", "interstitial collagenase", "stromelysin", "gelatinase", "macrophage elastase"; and "genetic polymorphism", "variant", "variation", "association". Additional studies were identified by a manual search from references of original studies or review articles on this topic. Only studies with full text articles published until October 2012 were included.

Study selection
---------------

The criteria for the papers selection were as follows: (1) studies with case-control or prospective longitudinal cohort design; (2) COPD as the outcome, with at least two comparison groups (COPD vs. healthy control groups); (3) the study including at least one of the four kinds of MMP polymorphisms (MMP1 -1607 1G/2G, MMP3 -1171 5A/6A, MMP9 -1562 C/T, MMP12 -82 A/G) in COPD cases and controls; (4) provide the available genotype frequency in COPD cases and healthy controls.

Data extraction
---------------

Information was carefully extracted from all eligible publications independently by two authors according to the inclusion criteria listed above. Once encountering disagreements, we resolved them by discussions with the third person. The data we extracted from papers contain basic information of study (author, publication year), population (sample size, ethnicity, age, lung function, and smoking index), COPD definition, genotype distribution in cases and controls, genotype identification method, Hardy-Weinberg equilibrium (HWE) test etc.

Data analysis
-------------

Odds ratio (OR) and 95% CIs were used to assess the strength of association between all kinds of MMP polymorphisms (MMP1 -1607 1G/2G, MMP3 -1171 5A/6A, MMP9 -1562 C/T, MMP12 -82 A/G) and COPD risk. Dominant, recessive and homozygote model were applied for genotype analysis.

Heterogeneity assumption was checked by the Cochran Q test. If p value for the Q test is over 0.10, we consider that there is lack of heterogeneity. We also used the statistic of I^2^ to detect the degree of heterogeneity, with I2 \< 25%, 25%--75% and \>75% to represent low, moderate and high degree of inconsistency, respectively[@b43][@b44]. In the analysis of pooled data, we used two different models according to the trait of the included studies: If no heterogeneity was found, a fixed effect model was adopted to determine the gene effect or the random effect model was used[@b45][@b46]. What\'s more, if heterogeneity across studies existed, subgroup analysis was performed to seek out the source of heterogeneity. Studies were subdivided by ethnicity (Caucasian versus Asian), genotyping methods (RFLP versus others), age (unmatched versus matched), smoking index (unmatched versus matched), lung function of COPD cases (FEV~1~ \> 50% prediction versus FEV~1~ \< 50% prediction) to find the source of any heterogeneity.

Hardy--Weinberg equilibrium (HWE) was tested in healthy control within each study. Deviation from HWE was tested using the χ^2^ test. Studies with controls that depart from HWE (p \< 0.05) were subjected to a sensitivity analysis in order to check the consistency of the overall effect.

We made use of Begg\'s funnel plot to examine the underlying publication bias, and also used Egger\'s weighted regression method to calculate P for bias[@b47][@b48]. If no publication bias existed, the funnel plot looked symmetrical.

All analyses were conducted with the use of Review Manager, V.5.0 (Revman, The Cochrane Collaboration) or STATA software, V.10.0 (STATA Corp).
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![Subgroup analysis of correlation between MMP9 polymorphism and COPD risk under two pairs of comparisons (CC + CT vs. TT; CC vs. TT).\
(a--b) The studies were divided into two groups according to age (unmatched or matched) under the comparison of CC + CT vs. TT (a) and CC vs. TT (b); (c--d) The studies were divided into three groups according to lung function (FEV1 \> 50% prediction, FEV1 \< 50% prediction or unknown) under the comparison of CC + CT vs. TT (c) and CC vs. TT (d); (e--f) The studies were divided into two groups according to genotype identification method (RFLP or Non-RFLP) under the comparison of CC + CT vs. TT (e) and CC vs. TT (f).](srep02818-f2){#f2}

![Publication bias on MMP polymorphism.\
(a) Begg\'s funnel plot of the 12 eligible studies assessing MMP1 -1607 1G/2G polymorphism; (b) Begg\'s funnel plot of the 11 eligible studies assessing MMP9 -1567 C/T polymorphism.](srep02818-f3){#f3}

###### Summary of 21 studies investigating association between MMP polymorphisms and COPD risk

                                                                                        sample size                lung function of COPD                                                                                                                         
  ------------------------------------- ------ --------------------------------------- ------------- ------ ----- ----------------------- --------------- --------------------------------------------- -------------------------------------------------------- ----------------------------
  Cai                                    2010                   Asian                       80         90    Yes            Yes            not mentioned                  not mentioned                        CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Cheng                                  2009                   Asian                       184       212    Yes            Yes             45.8 ± 8.6                     47.2 ± 16.3                                            ATS                                      PCR-RFLP
  Diemen [\#](#t1-fn3){ref-type="fn"}    2011                 Caucasian                     178       1117   Yes            Yes            not mentioned                  not mentioned                                           GOLD                                      Taqman
  Enewold                                2012                  African                      44        147    Yes            No             not mentioned                  not mentioned                                      not mentioned                        MassARRAY iPLEXTM platform
                                                              Caucasian                     123       191    Yes            No                                                                                                                                                 
  Han                                    2006                   Asian                       60         52    Yes            Yes            not mentioned                   45.2 ± 12.6                         CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Haq                                    2010                 Caucasian                     977       876    No             No              47.4 ± 12.1                    43.0 ± 15.1                                            GOLD                                   KASPar assay
  Hersh                                  2005                 Caucasian                     304       441    Yes            No              41.5 ± 8.2                     24.8 ± 6.5                    NETT inclusion standard [\#\#](#t1-fn4){ref-type="fn"}             Taqman
  Hua                                    2010                   Asian                       180       180    Yes            Yes            not mentioned                   50.3 ± 3.6                          CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Ito                                    2005                   Asian                       84         85    No             No              45.3 ± 9.8                     44.9 ± 17.4                                            GOLD                                     PCR-RFLP
  Korytina                               2008                 Caucasian                     318       319    No             Yes            not mentioned                   39.4 ± 17.8                                            GOLD                                     PCR-RFLP
  Korytina                               2012                 Caucasian                     391       514    No             No              58.7 ± 13.7                    41.7 ± 19.3                                            GOLD                                     PCR-RFLP
  Lee                                    2010                   Asian                       301       333    No             No              49.4 ± 13.1                    63.0 ± 26.2                                            GOLD                                  ABI sequencer
  Minematsu                              2001                   Asian                       45         65    Yes            Yes               49 ± 17                     not mentioned                         LAA score on chest CT-scans, LAA \> 8.0                    PCR-RFLP
  Santus                                 2009                 Caucasian                     147       133    Yes            No             not mentioned                    50.3 ± 16                                             GOLD                                  ABI sequencer
  Schirmer                               2009                 Caucasian                     111       101    No           Unknown          not mentioned                  not mentioned                                           GOLD                                     PCR-RFLP
  Sun                                    2005                   Asian                       59        109    Yes            Yes            not mentioned                  not mentioned                        CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Sun                                    2012                   Asian                       80         74    Yes            Yes            47.28 ± 10.09                  41.29 ± 15.59                        CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Tesfaigzi                              2006   Caucasian[\*](#t1-fn1){ref-type="fn"}       123       262    No             No             not mentioned   58.6 (19--99)[\*\*](#t1-fn2){ref-type="fn"}                            GOLD                                     PCR-RFLP
  Zhang                                  2004                   Asian                       148       197    Yes            Yes            52.44 ± 10.77                  52.3 ± 18.24                         CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Zhang                                  2005                   Asian                       147       120    No             Yes               53 ± 11                        53 ± 18                           CMA guideline [\#](#t1-fn3){ref-type="fn"}                  PCR-RFLP
  Zhou                                   2004                   Asian                       100        98    Yes            Yes            54.56 ± 9.85                   63.14 ± 17.37                                           GOLD                                     PCR-RFLP

\*The people recruited in this study consist of non-Hispanic white, Hispanic and others.

\*\*the data were shown as average (min - max).

^\#^The guideline was published by Chinese Medical Association (CMA) for diagnosis and treatment of COPD in 2002.

^\#\#^The cases were from NETT (National Emphysema Treatment Trial) according to standard as follows: 1. FEV1 \< 45% prediction, evidence of hyperinflation on pulmonary function testing; 2. Bilateral emphysema confirmed by HRCT.

###### the distribution of alleles and genotypes of MMPs in related studies

                                                Allele   Genotype                                                                                   
  ----------------------------------- -------- -------- ---------- -------- ---------- ---------- ---------- ---------- ---------- ---------- ----- ---------
  **MMP1 -1607 1G/2G (rs1799750)**     **1G**   **2G**    **1G**    **2G**   **1G1G**   **1G2G**   **2G2G**   **1G1G**   **1G2G**   **2G2G**        
  Cai                                   2010      34       126        56       124         6          22         52         15         26      49     0.002
  Cheng                                 2009     121       247       104       320         20         81         63         16         72      124    0.229
  Diemen                                2011     182       174       1155      1079        44         94         40        295        565      257    0.669
  Enewold                               2012     177       157       352       324         51         75         41         92        168      78     0.938
  Haq                                   2010     1006      948       911       841        273        460        244        228        455      193    0.231
  Hersh                                 2005     298       310       424       458         73        152         79        102        220      119    0.987
  Korytina                              2008     271       365       261       377         65        141        112         51        159      109    0.580
  Korytina                              2012     450       332       464       304        138        174         79        150        164      70     0.036
  Lee                                   2010     186       414       212       450         29        128        143         42        128      161    0.042
  Tesfaigzi                             2006     121       123       259       255         32         57         33         70        119      68     0.236
  Sun                                   2005      32        86        40       178         5          22         32         9          22      78     0.001
  Zhang                                 2005      92       202       102       138         15         62         70         31         40      49    \<0.001
  **MMP3 -1171 5A/6A (rs35068180)**    **5A**   **6A**    **5A**    **6A**   **5A5A**   **5A6A**   **6A6A**   **5A5A**   **5A6A**   **6A6A**        
  Cheng                                 2009     342        26       401        23        158         26         0         189         23       0     0.404
  Korytina                              2012      22       780        46       664         0          22        369         0          46      309    0.192
  Santus                                2009     140       154       131       135         25         90         32         36         59      38     0.194
  Schirmer                              2009      89        93        88       110         26         37         28         23         42      34     0.161
  Sun                                   2012      84        76        67        81         26         32         22         19         26      29     0.072
  **MMP9 -1562 C/T (rs3918242)**       **C**    **T**     **C**     **T**     **CC**     **CT**     **TT**     **CC**     **CT**     **TT**         
  Cheng                                 2009     233       135       320       104         76         81         27        124         72      16     0.229
  Han                                   2006      76        44        72        32         25         26         9          26         20       6     0.483
  Hua                                   2010     300        60       340        20        120         60         0         162         16       2     0.040
  Ito                                   2005     145        23       144        26         63         19         2          60         24       1     0.408
  Korytina                              2008     560        76       556        82        248         64         6         241         74       4     0.523
  Korytina                              2012     685        97       758       110        300         85         6         330         98       6     0.674
  Lee                                   2010     527        61       533        99        234         59         1         226         81       9     0.596
  Minematsu                             2001      68        22       114        16         25         18         2          50         14       1     0.986
  Schirmer                              2009     162        16       178        16         74         14         1          81         16       0     0.376
  Tesfaigzi                             2006     195        43       439        67         82         31         6         192         55       6     0.392
  Zhang                                 2005     253        41       215        25        106         41         0          98         19       3     0.097
  Zhou                                  2004     194        2        186        14         96         2          0          86         14       0     0.452
  **MMP12 -82 A/G (rs2276109)**        **A**    **G**     **A**     **G**     **AA**     **AG**     **GG**     **AA**     **AG**     **GG**         
  Diemen                                2011     308        56       1905      345        130         48         4         812        281      32     0.202
  Haq                                   2010     1749      205       1524      228        782        185         10        657        210       9     0.082
  Korytina                              2008     567        69       579        59        249         69         0         260         59       0     0.069
  Korytina                              2012     700        82       787        85        309         82         0         353         81       2     0.243
  Schirmer                              2009     194        28       186        16         84         26         1          85         16       0     0.387
  Zhang                                 2004     289        7        386        8         141         7          0         189         8        0     0.877

###### Pooled odds ratio for COPD susceptibility, heterogeneity and publication bias in meta-anlysis: comparison of alleles and genotypes

                                                                       Heterogeneity   Publication bias          
  ----------------------------------- ---- ------------------- ------ --------------- ------------------ ------- -------
  **MMP1 -1607 1G/2G (rs1799750)**                                                                                   
  1G vs. 2G                            12   0.99 (0.89, 1.10)   0.81        53%              0.01         0.945   0.980
  1G1G + 1G2G vs. 2G2G                 12   1.03 (0.86, 1.22)   0.76        58%             0.007           1     0.352
  1G1G vs. 1G2G + 2G2G                 12   0.99 (0.81, 1.21)   0.94        58%             0.006         0.244   0.274
  1G1G vs. 2G2G                        12   0.93 (0.77, 1.12)   0.44        38%              0.08         0.732   0.568
  **MMP3 -1171 5A/6A (rs35068180)**                                                                                  
  5A vs. 6A                            5    0.88 (0.61, 1.27)   0.50        71%             0.009         0.806   0.441
  5A5A + 5A6A vs. 6A6A                 4    0.92 (0.58, 1.46)   0.73        58%              0.07         0.089   0.100
  5A5Avs. 5A6A + 6A6A                  4    0.91 (0.58, 1.41)   0.66        50%              0.11         0.089   0.049
  5A5A vs. 6A6A                        3    1.18 (0.76, 1.82)   0.46        0%               0.42         0.296   0.210
  **MMP9 -1562 C/T (rs3918242)**                                                                                     
  C vs. T                              12   0.83 (0.62, 1.12)   0.22        79%            \<0.0001       0.732   0.953
  CC + CT vs. TT                       11   0.75 (0.45, 1.24)   0.26        22%              0.24         0.533   0.100
  CC vs. CT + TT                       12   0.80 (0.57, 1.14)   0.22        81%            \<0.0001       0.837   0.732
  CC vs. TT                            11   0.71 (0.40, 1.24)   0.23        31%              0.15         0.533   0.082
  **MMP12 -82 A/G (rs2276109)**                                                                                      
  A vs. G                              6    0.98 (0.80, 1.20)   0.82        44%              0.11         0.133   0.066
  AA + AG vs. GG                       4    1.14 (0.59, 2.20)   0.69        0%               0.70           1     0.862
  AA vs. AG + GG                       6    0.96 (0.76, 1.21)   0.72        52%              0.07         0.452   0.078
  AA vs. GG                            4    1.17 (0.61, 2.25)   0.64        0%               0.71           1     0.938
